Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase.
Olsson-Strömberg U, Höglund M, Björkholm M, Braide I, Carlson K, Gahrton G, Grimfors G, Hast R, Lerner R, Linder O, Ljungman P, Löfvenberg E, Malm C, Nilsson PG, Paul C, Rödjer S, Stenke L, Tidefeldt U, Turesson I, Uden AM, Wahlin A, Vilen L, Winqvist I, Zettervall O, Oberg G, Simonsson B. Olsson-Strömberg U, et al. Among authors: paul c. Leuk Lymphoma. 2006 Sep;47(9):1768-73. doi: 10.1080/10428190600611117. Leuk Lymphoma. 2006. PMID: 17064986
Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival.
Olsson-Strömberg U, Simonsson B, Ahlgren T, Björkholm M, Carlsson K, Gahrton G, Hast R, Löfvenberg E, Linder O, Ljungman P, Malm C, Paul C, Rödjer S, Turesson I, Udén AM, Wahlin A, Killander A, Wadman B, Westin J, Vikrot O, Zettervall O, Oberg G; Swedish CML Study Group. Olsson-Strömberg U, et al. Among authors: paul c. Hematol J. 2004;5(6):462-6. doi: 10.1038/sj.thj.6200552. Hematol J. 2004. PMID: 15570285 Clinical Trial.
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up.
Simonsson B, Oberg G, Bjoreman M, Bjorkholm M, Carneskog J, Karlsson K, Gahrton G, Grimfors G, Hast R, Karle H, Linder O, Ljungman P, Nielsen JL, Nilsson J, Lofvenberg E, Malm C, Olsson K, Olsson-Stromberg U, Paul C, Stenke L, Stentoft J, Turesson I, Udén AM, Wahlin A, Vilén L, Weis-Bjerrum O. Simonsson B, et al. Among authors: paul c. Acta Haematol. 2005;113(3):155-62. doi: 10.1159/000084445. Acta Haematol. 2005. PMID: 15870485 Clinical Trial.
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.
Gruber A, Björkholm M, Brinch L, Evensen S, Gustavsson B, Hedenus M, Juliusson G, Löfvenberg E, Nesthus I, Simonsson B, Sjo M, Stenke L, Tangen JM, Tidefelt U, Udén AM, Paul C, Liliemark J. Gruber A, et al. Among authors: paul c. Leuk Res. 2003 Apr;27(4):323-8. doi: 10.1016/s0145-2126(02)00181-9. Leuk Res. 2003. PMID: 12531223 Clinical Trial.
High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia.
Hallböök H, Simonsson B, Ahlgren T, Björkholm M, Carneskog J, Grimfors G, Hast R, Karlsson K, Kimby E, Lerner R, Linder O, Linderholm M, Löfvenberg E, Malm C, Nilsson PG, Paul C, Stenke L, Stockelberg D, Tidefelt U, Turesson I, Uden-Blome AM, Vilen L, Wahlin A, Winquist I, Smedmyr B. Hallböök H, et al. Among authors: paul c. Br J Haematol. 2002 Sep;118(3):748-54. doi: 10.1046/j.1365-2141.2002.03685.x. Br J Haematol. 2002. PMID: 12181041 Free article. Clinical Trial.
Long-term follow-up of patients >or=60 yr old with acute myeloid leukaemia treated with intensive chemotherapy.
Oberg G, Killander A, Björeman M, Gahrton G, Grimfors G, Gruber A, Hast R, Lerner R, Liliemark J, Mattson S, Paul C, Simonsson B, Stalfelt AM, Stenke L, Tidefelt U, Udén AM, Björkholm M; LGMS. Oberg G, et al. Among authors: paul c. Eur J Haematol. 2002 Jun;68(6):376-81. doi: 10.1034/j.1600-0609.2002.00423.x. Eur J Haematol. 2002. PMID: 12225396 Clinical Trial.
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease.
Hast R, Hellström-Lindberg E, Ohm L, Björkholm M, Celsing F, Dahl IM, Dybedal I, Gahrton G, Lindberg G, Lerner R, Linder O, Löfvenberg E, Nilsson-Ehle H, Paul C, Samuelsson J, Tangen JM, Tidefelt U, Turesson I, Wahlin A, Wallvik J, Winquist I, Oberg G, Bernell P. Hast R, et al. Among authors: paul c. Leukemia. 2003 Sep;17(9):1827-33. doi: 10.1038/sj.leu.2403035. Leukemia. 2003. PMID: 12970783 Clinical Trial.
A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic Leukemia.
Paul C, Tidefelt U, Gahrton G, Björkholm M, Järnmark M, Killander A, Kimby E, Liliemark J, Lindeberg A, Lindquist R, Lockner D, Lönnqvist B, Mellstedt H, Merk K, Palmblad J, Peterson C, Simonsson B, Stalfelt AM, Sundström C, Wadman B, Wedelin C, Udén AM, Öberg G, Öst Å. Paul C, et al. Leuk Lymphoma. 1991;3(5-6):355-64. doi: 10.3109/10428199109070279. Leuk Lymphoma. 1991. PMID: 27467426
2,138 results